(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical ...

Women who’ve been treated for hormone-sensitive breast cancer often face five to 10 years of endocrine therapy to lower the chances of their tumors coming back. Because that drug regimen is toxic ...

As cancer treatments improve, the population of cancer survivors grows. Fred Hutchinson Cancer Center understands the need to support survivors with uniquely tailored follow-up care. Recently ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

Endocrine therapy is one of the top predictors of sexual dysfunction in women cancer survivors, according to a study shown at ...

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...

Please provide your email address to receive an email when new articles are posted on . “Endocrine therapy is the mainstay of treatment for patients with localized and metastatic ...

Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid ...